Zynerba Pharmaceuticals Stock News

– Poster presentation highlights design enhancements incorporated into pivotal RECONNECT trial –

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc said it will deliver oral and poster presentations on its CBD gel Zygel at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2022), hel

– Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 –

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has reported results for the first quarter that reveal ample cash on hand, giving the company scope to run pivotal trials of its flagship product Zygel (ZYN00

– Data support the long-term safety and effectiveness of Zygel –

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc, a leader in transdermal cannabinoid therapies for rare neuropsychiatric disorders, revealed that it is making an oral podium presentation at the Internationa

DEVON, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

DEVON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc said it presented a poster on the long-term safety and efficacy of its cannabidiol transdermal gel, Zygel, at the 2022 Society of Biological Psychiatry (SOBP)

DEVON, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-ra

DEVON, Pa., April 05, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

Zynerba (ZYNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we mak

New York, March 02, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Marvel Discovery completes airborne magnetic survey on Gander East project click here Canaccord Genuity calls Zynerba "undervalued," reiterates ''Buy'' rating after positive 4Q results click here Infield Minerals plans to advance Desperado property with 2,000-meter reverse circulation drilling campaign click here Viscount Mining announces results from New Century-Rattlesnake target in Cherry Creek, Nevada click here Stifel GMP repeats ''Buy'' on Steppe Gold as it restarts heap leach processing to recover gold and silver at its ATO mine in Mongolia click here Kootenay Silver says JV partner Aztec Minerals hits "best hole yet" at Cervantes project in Mexico click here MedX Health strikes agreement with Health Partners to launch tele dermatology screening platform in the UK click here Healixa secures an additional $22.

Canaccord Genuity (TSX:CF, LSE:CF) said it continued to believe that Zynerba Pharmaceuticals (NASDAQ:ZYNE) is undervalued after the company reported its fourth-quarter financial results that showed a